Compare AEO & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEO | DNLI |
|---|---|---|
| Founded | 1977 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.7B |
| IPO Year | 2004 | 2017 |
| Metric | AEO | DNLI |
|---|---|---|
| Price | $17.00 | $23.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 14 |
| Target Price | $21.09 | ★ $34.33 |
| AVG Volume (30 Days) | ★ 3.6M | 1.9M |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $5,547,236,000.00 | N/A |
| Revenue This Year | $5.22 | N/A |
| Revenue Next Year | $3.38 | $408.85 |
| P/E Ratio | $122.04 | ★ N/A |
| Revenue Growth | ★ 4.10 | N/A |
| 52 Week Low | $10.29 | $12.58 |
| 52 Week High | $28.46 | $27.30 |
| Indicator | AEO | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 50.70 | 45.21 |
| Support Level | $17.05 | $18.27 |
| Resistance Level | $18.30 | $23.27 |
| Average True Range (ATR) | 0.73 | 1.38 |
| MACD | 0.06 | -0.39 |
| Stochastic Oscillator | 67.35 | 17.58 |
American Eagle Outfitters Inc is a specialty retailer. The company is engaged in the retail of apparel and accessories with company stores in the United States, Canada, Mexico, and Hong Kong. The Company leases all store premises, regional distribution facilities, some of its office space, and certain information technology and office equipment. American Eagle also has its online business. It operates in two segments: American Eagle and Aerie. The majority of its revenue comes from its primary brand, American Eagle, which offers an assortment of specialty apparel, accessories, and personal care products for women and men. Geographically, it generates the majority of its revenue from the United States.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.